Sugi Predict

Sugi Predict / Compounds / SCHEMBL736065

SCHEMBL736065

SCHEMBL736065

Nc1ccc(S(=O)(=O)Cc2cscn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.44
▸ TSHR P16473 4/20 0.38
▸ LMNA P02545 3/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ MPO P05164 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ AURKA O14965 1/20 0.38
▸ DHFR P00374 1/20 0.38
▸ CYP2C19 P33261 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816170 0.84 ALDH1A1 (0.49) LMNACYP3A4SLC6A3HPGDALDH1A1
SCHEMBL9047983 0.74 GAA (0.44) GAATSHRLMNACYP2C9MPO
SCHEMBL20502514 0.73 GAA (0.39) GAATSHRLMNASLC6A3PKM
SCHEMBL5155173 0.73 SLC6A3 (0.38) GAATSHRLMNACYP3A4SLC6A3
Hydrochloric Acid SCHEMBL20502515 0.72 GAA (0.38) GAATSHRLMNASLC6A3PKM
SCHEMBL20497555 0.72 SLC6A3 (0.36) GAATSHRLMNASLC6A3PKM
SCHEMBL19332377 0.71 GAA (0.44) GAATSHRLMNACYP2C9MPO
SCHEMBL20498427 0.70 SLC6A3 (0.38) GAATSHRLMNASLC6A3PKM
SCHEMBL5155166 0.70 SLC6A3 (0.40) GAATSHRLMNASLC6A3PKM
SCHEMBL4834138 0.69 GFER (0.52) TSHRCYP3A4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11414410-B2 Inhibitors of protein kinases ALEXION PHARMACEUTICALS, INC. (US) 2022-08-16 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2020-07-30 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2014-01-30 — — US disclosed
US-8501944-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-08-06 — — US disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 — — US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 — — US disclosed
EP-2321283-A1 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS Portola Pharmaceuticals, Inc. (US) 2011-05-18 — — EP disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 — — US disclosed
WO-2009145856-A1 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 GAA 2777/4885TSHR 2801/4885LMNA 4015/4885
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 GAA 2777/4885TSHR 2801/4885LMNA 4015/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GAA 742/4885TSHR 1137/4885LMNA 3015/4885
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 GAA 2777/4885TSHR 2801/4885LMNA 4015/4885
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 GAA 2777/4885TSHR 2801/4885LMNA 4015/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK GAA 742/4885TSHR 1137/4885LMNA 3015/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 GAA 499/4885TSHR 2361/4885LMNA 3020/4885
US-11414410-B2 Inhibitors of protein kinases MAP3K1, MAP3K20, MAP3K2 GAA 3176/4885TSHR 4397/4885LMNA 3562/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GAA 698/4885TSHR 1024/4885LMNA 3115/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GAA 698/4885TSHR 1024/4885LMNA 3115/4885
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 GAA 2777/4885TSHR 2801/4885LMNA 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.